ロード中...
Mortality Benefit of Alirocumab: A Bayesian Perspective
BACKGROUND: The ODYSSEY OUTCOMES (Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome) trial demonstrated that alirocumab reduced major cardiovascular events. However, because of the hierarchical testing strategy used for the multiple outcomes examined, the observed reduction in all...
保存先:
| 出版年: | J Am Heart Assoc |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6818032/ https://ncbi.nlm.nih.gov/pubmed/31599200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013170 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|